{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:35:51Z","timestamp":1785404151043,"version":"3.56.0"},"reference-count":30,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["IGH-155179"],"award-info":[{"award-number":["IGH-155179"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"award":["IGH-155179"],"award-info":[{"award-number":["IGH-155179"]}],"id":[{"id":"https:\/\/ror.org\/01gavpb45","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: This study was conducted to evaluate the population-level healthcare resource utilization (HCRU) and costs for men diagnosed with low-risk prostate cancer (PCa) either on active surveillance (AS) or not on AS, in which AS was defined as receiving no treatment within 1 year of diagnosis and two biopsies. Methods: AS men aged 40 to 105 years, diagnosed with stage I or II PCa, had a prostate-specific antigen (PSA) level &lt; 20 ng\/mL, a Gleason score between 5 and 7, and were matched (1:1) with men not receiving AS. The index date is defined as the date 1 year after PCa diagnosis. HCRU and costs were assessed using a macro-based costing methodology and costs standardized to 2023 CAD. Means (SD) and medians (interquartile ranges) per person-year values were reported annually. Results: During the year leading up to the index date, the mean number of HCRU per patient-year (PPY) was significantly lower for the AS cases versus non-AS in terms of cancer clinic visits (1.7 vs. 26.7), hospital outpatient clinic visits (3.6 vs. 4.9), all physician visits (16.3 vs. 17.5), and specialist visits (10.7 vs. 11.6). The mean overall cost PPY was $6100 \u00b1 $12,400 for AS cases and $10,400 \u00b1 $17,800 for non-AS men (median overall cost PPY= $3500 [IQR: $2100\u2013$5700] vs. $3700 [IQR: $2100\u2013$7200] (p = 0.0001, respectively). Conclusions: HCRU and costs calculated for AS and non-AS low-risk PCa men indicate the cost savings potential for AS.<\/jats:p>","DOI":"10.3390\/cancers18101580","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:46:55Z","timestamp":1778676415000},"page":"1580","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population-Level Resources and Costs Associated with Low-Risk Prostate Cancer Patients on Active Surveillance"],"prefix":"10.3390","volume":"18","author":[{"given":"Soo Jin","family":"Seung","sequence":"first","affiliation":[{"name":"HOPE Research Centre, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Bayani","sequence":"additional","affiliation":[{"name":"Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Institute for Clinical Evaluative Sciences, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute for Clinical Evaluative Sciences, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi","family":"Gatley","sequence":"additional","affiliation":[{"name":"Institute for Clinical Evaluative Sciences, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisia","family":"Wong","sequence":"additional","affiliation":[{"name":"HOPE Research Centre, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Richard","sequence":"additional","affiliation":[{"name":"HOPE Research Centre, Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Barker","sequence":"additional","affiliation":[{"name":"Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8197-6272","authenticated-orcid":false,"given":"Anna Ying-Wah","family":"Lee","sequence":"additional","affiliation":[{"name":"Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M. S.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine & Pathobiology, University of Edinburgh, Edinburgh EH8 9YL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Berman","sequence":"additional","affiliation":[{"name":"Department of Pathology & Molecular Medicine, Queen\u2019s University, Kingston, ON K7L 3N6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4883-1781","authenticated-orcid":false,"given":"Andrew","family":"Loblaw","sequence":"additional","affiliation":[{"name":"Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig C.","family":"Earle","sequence":"additional","affiliation":[{"name":"Institute for Clinical Evaluative Sciences, Toronto, ON M4N 3M5, Canada"},{"name":"Canadian Partnership Against Cancer, Toronto, ON M5H 1J8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Mittmann","sequence":"additional","affiliation":[{"name":"Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"ref_1","unstructured":"Canadian Cancer Society\/Soci\u00e9t\u00e9 Canadienne du Cancer (2024, July 08). PCa Statistics. Available online: https:\/\/cancer.ca\/en\/cancer-information\/cancer-types\/prostate\/statistics."},{"key":"ref_2","first-page":"457","article-title":"NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer, Version 2.2023","volume":"21","author":"Mohler","year":"2023","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline","volume":"208","author":"Eastham","year":"2022","journal-title":"J. Urol."},{"key":"ref_4","first-page":"72","article-title":"Active surveillance in men with low-risk prostate cancer: Current and future challenges","volume":"1","author":"Han","year":"2013","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"ref_5","unstructured":"Cancer Care Ontario (2024, July 09). Prostate Cancer Surveillance: A Guide for Primary Care Providers. Available online: https:\/\/www.cancercareontario.ca\/sites\/ccocancercare\/files\/assets\/CCOProstateSurveillanceGuide.PDF."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/cncr.32557","article-title":"Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts","volume":"126","author":"Lange","year":"2019","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/JU.0000000000003097","article-title":"Long-term outcomes following active surveillance of low-grade PCa: A population-based study using a landmark approach","volume":"209","author":"Timilshina","year":"2023","journal-title":"J. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","article-title":"Long-term follow-up of a large active surveillance cohort of patients with PCa","volume":"33","author":"Klotz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"E60","DOI":"10.9778\/cmajo.20130037","article-title":"Active surveillance for low-risk prostate cancer compared with immediate treatment: A Canadian cost comparison","volume":"2","author":"Dragomir","year":"2014","journal-title":"CMAJ Open"},{"key":"ref_10","unstructured":"Kuwornu, P., Wodchis, W., and Calzavara, A. (2017). A Methodological Guide on Using the GETCOST Macro for Costing Studies, ICES Central."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.21037\/jgo-23-155","article-title":"Real-world treatment patterns and survival outcomes for treated biliary tract cancer patients using administrative databases in Ontario","volume":"14","author":"Seung","year":"2023","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_12","unstructured":"Wodchis, W., Bushmeneva, K., Nikitovic, M., and McKillop, I. (2013). Guidelines on Person-Level Costing Using Administrative Databases in Ontario, Health System Performance Research Network. Available online: https:\/\/hspn.ca\/wp-content\/uploads\/2025\/01\/Report-Guidelines-on-Personal-Level-Costing-One-Page-Brief-1.pdf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.36469\/jheor.2021.29145","article-title":"Real-world treatment patterns, survival, and costs for ovarian cancer in Canada: A retrospective cohort study using provincial administrative data","volume":"8","author":"Hurry","year":"2021","journal-title":"J. Health Econ. Outcomes Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.euros.2020.11.004","article-title":"Real-world evidence to estimate prostate cancer costs for first-line treatment or active surveillance","volume":"23","author":"Magnani","year":"2021","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/JU.0000000000000345","article-title":"Cost-effectiveness of active surveillance, radical prostatectomy and external beam radiotherapy for localized PCa: An analysis of the PROTECT trial","volume":"202","author":"Sharma","year":"2019","journal-title":"J. Urol."},{"key":"ref_16","unstructured":"Choosing Wisely Canada (2024, July 09). Low-Risk PCa. Available online: https:\/\/choosingwiselycanada.org\/pamphlet\/low-risk-prostate-cancer\/."},{"key":"ref_17","unstructured":"Cancer Care Ontario (2024, July 05). Active Surveillance for the Management of Localized PCa. Available online: https:\/\/www.cancercareontario.ca\/en\/guidelines-advice\/types-of-cancer\/2286."},{"key":"ref_18","unstructured":"Canadian Cancer Society (2024, July 10). Active Surveillance for PCa. Available online: https:\/\/cancer.ca\/en\/cancer-information\/cancer-types\/prostate\/treatment\/active-surveillance."},{"key":"ref_19","first-page":"195","article-title":"Patient reported outcomes and treatment-associated complications as a consideration in selecting localized prostate cancer management","volume":"17","author":"Nguyen","year":"2025","journal-title":"Res. Rep. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/pon.5947","article-title":"Why do men with PCa discontinue active surveillance for definitive treatment? A mixed methods investigation","volume":"31","author":"McIntosh","year":"2022","journal-title":"Psychooncology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.euo.2022.09.001","article-title":"Long-term health-related quality of life in patients on active surveillance for prostate cancer: A systematic review","volume":"6","author":"Thompson","year":"2023","journal-title":"Eur. Urol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/iju.14202","article-title":"Quality of life in active surveillance for early prostate cancer","volume":"27","author":"Kato","year":"2020","journal-title":"Int. J. Urol."},{"key":"ref_23","unstructured":"MyHealth Alberta (2024, March 18). Active Surveillance for Prostate Cancer. Available online: https:\/\/myhealth.alberta.ca\/Health\/pages\/conditions.aspx?hwid=abo8743."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.eururo.2017.07.018","article-title":"Active surveillance versus watchful waiting for localized prostate cancer: A model to inform decisions","volume":"72","author":"Loeb","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1311593","article-title":"Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer","volume":"370","author":"Holmberg","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.euo.2023.01.003","article-title":"Best current practice and research priorities in active surveillance for prostate cancer\u2014A report of a Movember international consensus meeting","volume":"6","author":"Moore","year":"2023","journal-title":"Eur. Urol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.31128\/AJGP-06-23-6866","article-title":"When less is more: Updates in active surveillance and watchful waiting in the management of prostate cancer","volume":"53","author":"Homewood","year":"2024","journal-title":"Aust. J. Gen. Pract."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.ejca.2006.02.011","article-title":"Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials","volume":"42","author":"Collette","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_29","first-page":"15","article-title":"The present and future of biomarkers in prostate cancer: Proteomics, genomics, and immunology advancements","volume":"8","author":"Gaudreau","year":"2016","journal-title":"Biomark. Cancer"},{"key":"ref_30","first-page":"djv224","article-title":"Population-based study to determine the health system costs of using the 21-gene assay","volume":"107","author":"Mittmann","year":"2015","journal-title":"J. Natl. Cancer Inst."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/10\/1580\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:11:14Z","timestamp":1778677874000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/10\/1580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["cancers18101580"],"URL":"https:\/\/doi.org\/10.3390\/cancers18101580","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]}}}